Drug updated on 4/29/2024
| Dosage Form | Injection (intravenous; 300 mg/10 ml) |
| Drug Class | CD20-directed cytolytic antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Indicated for the treatment of primary progressive MS in adults.
Summary
- Ocrelizumab (Ocrevus) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults; it's also used to treat primary progressive MS in adults.
- A total of 13 systematic reviews/meta-analyses were reviewed to gather information about this drug.
- In terms of safety, ocrelizumab has been associated with a higher risk of infections compared to some other monoclonal antibodies; these include upper respiratory infections, urinary tract infections, and nasopharyngitis.
- The same documents revealed that reduced immunoglobulin G (IgG) levels correlated with an increased infection risk over time for patients treated with ocrelizumab; however IgG levels appeared relatively stable over time in trials involving another drug called Ofatumumab.
- When comparing adverse events among high-efficacy DMTs such as Alemtuzumab and others, Ocrevus showed a comparable rate indicating its relative safety within its class despite presenting risks like any other medication.
- As per effectiveness comparison against other treatments for relapsing forms of MS: alemtuzumab and natalizumab/ofatumamub along side ocrelizmub emerged as top three most efficacious treatments depending on confirmed disability progression definition used making it highly effective option for managing RMS.
- For primary progressive MS specifically where treatment options are notably limited,ocrelizuamb was found to be the most efficient monoclonal antibody according to the studys reviewed.
- Observations from population specifics & subgroup considerations indicate that Ocrilizuamb plays significant role treating PMS effectively which makes it recommended choice especially when symptoms worsen steadily underscoring importance tailored treatment strategies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ocrevus (Ocrelizumab) Prescribing Information. | 2024 | Genentech USA, Inc., South San Francisco, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Ocrelizumab (Ocrevus®) protocol for the treatment of relapsing multiple sclerosis (RMS). | 2020 | Health Service Executive |
| UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. | 2019 | Practical Neurology |